Here's Why BioMarin Pharmaceutical Leapt 10.2% in November
The business reported a handful of positive developments.
BioMarin Pharmaceutical
BMRN
BMRN
$78.90
-$1.02
-1.3%
BATS BZX Real Time Price as of December 9, 2019, 4:00 p.m. EST
View Interactive BMRN Charts
The Company develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
News & Analysis: BioMarin Pharmaceutical
The Fool has written over 200 articles on BioMarin Pharmaceutical.
2 Beaten-Down Biotech Stocks That Could Make You Rich
BioMarin and Sarepta Therapeutics should be top growth plays in the next decade.
3 Reasons BioMarin Pharmaceutical Stock Is a Buy Right Now
BioMarin's stock is poised for big gains in 2020. Here's why.
Biomarin Pharmaceutical Inc (BMRN) Q3 2019 Earnings Call Transcript
BMRN earnings call for the period ending September 30, 2019.
2 High-Growth Stocks to Buy Right Now
BioMarin Pharmaceutical and Vertex Pharmaceuticals should prove to be outstanding growth vehicles in 2020 and beyond.
BioMarin's Roller Coaster Continues
Long-term investors need to learn to stomach the ride.
Biomarin Pharmaceutical Inc (BMRN) Q2 2019 Earnings Call Transcript
BMRN earnings call for the period ending June 30, 2019.
3 Top Biotech Stocks to Buy in July
Here's why this team of biotech experts are giddy about these stocks right now.
3 Top Growth Stocks to Buy in June
If you have some cash to put to work, you'll want to take a look at these three companies from the tech, drug, and industrial sectors.
How BioMarin May Revolutionize the Hemophilia Treatment Market
The latest trial results for its hemophilia A gene therapy suggest it may eliminate or significantly reduce the need for weekly infusions.
